Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Natalia Palazón"'
Autor:
Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients D
Externí odkaz:
https://doaj.org/article/212d6baeaf2d4c8bb7bf0ab05ba40793
Autor:
Carlos Jiménez-Cortegana, Elena Salamanca, Natalia Palazón-Carrión, Flora Sánchez-Jiménez, Antonio Pérez-Pérez, Teresa Vilariño-García, Sandra Fuentes, Salomón Martín, Marta Jiménez, Raquel Galván, Carmen Rodríguez-Chacón, Catalina Sánchez-Mora, Elisa Moreno-Mellado, Belén Gutiérrez-Gutiérrez, Nerissa Álvarez, Alberto Sosa, José Garnacho-Montero, Luis de la Cruz-Merino, Jesús Rodríguez-Baño, Víctor Sánchez-Margalet
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences in the severity, complications and outcomes of the COVID-19 are intriguing and, patients with similar baseline clinical conditions
Externí odkaz:
https://doaj.org/article/e106077a792e43cf9b36806d4c0e7273
Autor:
Natalia Palazón-Carrión, Carlos Jiménez-Cortegana, M. Luisa Sánchez-León, Fernando Henao-Carrasco, Esteban Nogales-Fernández, Massimo Chiesa, Rosalía Caballero, Federico Rojo, María-Adoración Nieto-García, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, the Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cell
Externí odkaz:
https://doaj.org/article/f7ffda4053d44faa99e7001d804ed3ac
Autor:
Carlos Martínez-Chinchilla, Lucía Vazquez-Montero, Natalia Palazón-Carrión, Isabel M. Fernández-Román, José López-Barba, Luis de la Cruz-Merino, Jesús Rodríguez-Baño, Zaira R. Palacios-Baena
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunosuppressant conditions such as hematological malignancies increase the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It has been described in the literature that patients on anti-CD20 maintenance therapies for
Externí odkaz:
https://doaj.org/article/5eeac605929f4ee09ddedbdb21e980fc
Autor:
Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or r
Externí odkaz:
https://doaj.org/article/b89f60e62bf043c59fe379aa70ec66e3
Autor:
Natalia Palazón‑Carrión, Carlos Jiménez‑Cortegana, M. Luisa Sánchez‑León, Fernando Henao‑Carrasco, Esteban Nogales‑Fernández, Massimo Chiesa, Rosalía Caballero, Federico Rojo, María‑Adoración Nieto‑García, Víctor Sánchez‑Margalet, Luis de la Cruz‑Merino, the Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/7cb81409be9d4aa6a04463d97674463c
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf9183a00b8270cb46c8800a40d5d32
https://doi.org/10.1158/1078-0432.22487339
https://doi.org/10.1158/1078-0432.22487339
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Purpose:New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.Patients and Methods:In the phase II R2-GDP trial, 78 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f3c37b5b07b0c28088ac4cb012473f
https://doi.org/10.1158/1078-0432.c.6532499
https://doi.org/10.1158/1078-0432.c.6532499
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5587b44b63c51aeac3b6410ed474a9
https://doi.org/10.1158/1078-0432.22487342
https://doi.org/10.1158/1078-0432.22487342
Autor:
Maribel Casas, Josefina Cruz, Natalia Palazón, Asunción Soto, Rosalia Caballero, Luz Milva Rodriguez Rodriguez, Manuel Ramos, Jose Luis Alonso, María Gion, Massimo Chiesa, Federico Rojo, Fernando Moreno, Luis F. De La Cruz, Javier Cortes, Alfonso Cortés, Marta Santisteban, Esther Holgado, Vanesa Quiroga, Susana Bezares, Raquel Andrés
Publikováno v:
Cancer Research. 81:PS4-38
Background Immune cells (ICs) infiltration and immune checkpoints have been shown to be important for BC patients’ (pts) prognosis and response to immunotherapy. We aimed to analyze the relation between TILs prevalence and PD-L1 expression with eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9053f0923b30fe489c3e31ad5f434081
https://doi.org/10.1158/1538-7445.sabcs20-ps4-38
https://doi.org/10.1158/1538-7445.sabcs20-ps4-38